Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/192182
Title: | Neurological Complications of Conventional and Novel Anticancer Treatments |
Author: | Alberti, Paola Salvalaggio, Alessandro Argyriou, Andreas A. Bruna, Jordi Visentin, Andrea Cavaletti, Guido Briani, Chiara |
Keywords: | Neurotoxicologia Quimioteràpia del càncer Immunoteràpia Neurotoxicology Cancer chemotherapy Immunotheraphy |
Issue Date: | 10-Dec-2022 |
Publisher: | MDPI AG |
Abstract: | Simple Summary Cancer survivors can experience neurological complications after exposure to anticancer therapy. Chemotherapy-induced peripheral neurotoxicity (CIPN), mainly consisting of sensory loss and neuropathic pain in hands and feet, is most commonly encountered. Cognitive impairment, although less frequent, is also a severe adverse event, significantly diminishing patients' quality of life. The introduction of immunotherapy has resulted in durable remissions in several types of solid tumor malignancies, although severe neurological immune-related adverse events involving both the central and peripheral nervous system can occur in up to 10% of patients. We herein describe what it is currently known on the topic, and provide directions for future neuroprotection and symptomatic treatment studies. Various neurological complications, affecting both the central and peripheral nervous system, can frequently be experienced by cancer survivors after exposure to conventional chemotherapy, but also to modern immunotherapy. In this review, we provide an overview of the most well-known adverse events related to chemotherapy, with a focus on chemotherapy induced peripheral neurotoxicity, but we also address some emerging novel clinical entities related to cancer treatment, including chemotherapy-related cognitive impairment and immune-mediated adverse events. Unfortunately, efficacious curative or preventive treatment for all these neurological complications is still lacking. We provide a description of the possible mechanisms involved to drive future drug discovery in this field, both for symptomatic treatment and neuroprotection. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/cancers14246088 |
It is part of: | Cancers, 2022, vol. 14, num. 24, p. 6088 |
URI: | http://hdl.handle.net/2445/192182 |
Related resource: | https://doi.org/10.3390/cancers14246088 |
ISSN: | 2072-6694 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
cancers-14-06088-v3.pdf | 1.46 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License